MXCT (MaxCyte) Days Payable : 66.69 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is MaxCyte Days Payable?

MaxCyte's average Accounts Payable for the three months ended in Sep. 2024 was $1.41 Mil. MaxCyte's Cost of Goods Sold for the three months ended in Sep. 2024 was $1.93 Mil. Hence, MaxCyte's Days Payable for the three months ended in Sep. 2024 was 66.69.

The historical rank and industry rank for MaxCyte's Days Payable or its related term are showing as below:

MXCT' s Days Payable Range Over the Past 10 Years
Min: 40.28 Med: 369.19 Max: 972.1
Current: 64.94

During the past 12 years, MaxCyte's highest Days Payable was 972.10. The lowest was 40.28. And the median was 369.19.

MXCT's Days Payable is ranked worse than
53.41% of 792 companies
in the Medical Devices & Instruments industry
Industry Median: 69.87 vs MXCT: 64.94

MaxCyte's Days Payable declined from Sep. 2023 (117.95) to Sep. 2024 (66.69). It may suggest that MaxCyte accelerated paying its suppliers.

MaxCyte Days Payable Historical Data

The historical data trend for MaxCyte's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MaxCyte Days Payable Chart

MaxCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Payable

Get a 7-Day Free Trial

227.92

196.48

135.61

75.61

39.83

MaxCyte Quarterly Data
	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Days Payable	Get a 7-Day Free Trial															117.95	34.52	78.60	80.55	66.69

Competitive Comparison of MaxCyte's Days Payable

For the Medical Devices subindustry, MaxCyte's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MaxCyte's Days Payable Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Days Payable distribution charts can be found below:

* The bar in red indicates where MaxCyte's Days Payable falls into.

MaxCyte Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

MaxCyte's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (0.292	+	0.743)	/	2 )	/	4.742	*	365
=	0.5175					/	4.742	*	365
=	39.83

MaxCyte's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (0.953	+	1.865)	/	2 )	/	1.928	*	365 / 4
=	1.409					/	1.928	*	365 / 4
=	66.69

MaxCyte Days Payable Related Terms

Thank you for viewing the detailed overview of MaxCyte's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

MaxCyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MaxCyte Inc (NAS:MXCT) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

MXCT:UK

Address

9713 Key West Avenue, Suite 400, Rockville, MD, USA, 20850

Website

https://www.maxcyte.com

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Executives

Stanley C Erck	director	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Joseph Johnston	director	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Thomas M. Ross	officer: EVP, Global Sales	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Maher Masoud	officer: EVP and General Counsel	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Douglas Doerfler	director, officer: President and CEO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Richard Douglas	director	ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Douglas J Swirsky	officer: Chief Financial Officer	C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Patrick J Balthrop	director	C/O MAXCYTE, INC., 9713 KEY WEST AVENUE, SUITE 400, ROCKVILLE MD 20850
Casdin Partners Master Fund, L.p.	10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Cenk Sumen	officer: Chief Scientific Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Amanda Louise Murphy	officer: Chief Financial Officer	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Ron Holtz	officer: SVP and CAO	C/O MAXCYTE, INC., 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
Yasir B. Al-wakeel	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Art Mandell	director	C/O MAXCYTE, INC., C/O 22 FIRSTFIELD ROAD, SUITE 110, GAITHERSBURG MD 20878
William W Brooke	director	2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203